MedTrace Logo

Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With Upper Respiratory Tract Infection

NCT04930900 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-07-29

No results posted yet for this study

Summary

This is a Phase 1, single-dose, two-period study that will consist of a combined screening and baseline period and an open-label treatment period. Subjects will be enrolled when they experience an Upper Respiratory Tract Infection with nasal congestion and edema.

Conditions

Interventions

DRUG

ARS-1 with URTI

ARS-1

DRUG

ARS-1 without URTI

ARS-1 without URTI

Sponsors & Collaborators

  • ARS Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Anthony McGirr, MD · Northern Beach Clinical Research Pty Ltd,

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-09
Primary Completion
2022-03-31
Completion
2022-07-25
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04930900 on ClinicalTrials.gov